Gleevec Clinical Trials
Here are the 6 most popular medical studies for gleevec
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Burbank, California
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitors for Hypereosinophilic Syndrome
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is for patients with a rare blood disorder called hypereosinophilic syndrome, who have not responded to standard treatment. The study will test whether the drug imatinib mesylate (Gleevec) is safe and effective in reducing blood eosinophils in these patients.
Tyrosine Kinase Inhibitor
Ruxolitinib + Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial will compare the different tyrosine kinase inhibitors, with and without ruxolitinib, to see how well they work in treating patients with chronic myeloid leukemia.
Popular filter options for gleevec trials
Phase 3 Clinical Trials
View 29 phase 3 medical studies.
Tyrosine Kinase Inhibitor
Imatinib + Chemotherapy for Acute Lymphoblastic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying the combination of imatinib mesylate with two different chemotherapy regimens to treat patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.
Tyrosine Kinase Inhibitor
Imatinib for COVID-19
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Clinical Trials With No Placebo
View 29 medical studies that do not have a placebo group.
Tyrosine Kinase Inhibitor
Imatinib + Chemotherapy for Acute Lymphoblastic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying the combination of imatinib mesylate with two different chemotherapy regimens to treat patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.
MEK Inhibitor
MEK162 + Imatinib for Gastrointestinal Stromal Tumor
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing the effects of two drugs, MEK162 and imatinib, on Gastrointestinal Stromal Tumor (GIST). The funding for this trial comes from the FDA Office of Orphan Products Development and Array/Pfizer.
Histone Deacetylase Inhibitor; Tyrosine Kinase Inhibitor
Imatinib; LBH589 for Chordoma
Recruiting3 awardsPhase 1
Boston, Massachusetts
This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma. For the recurrent population, those patients that do not require immediate surgical resection will be eligible. Patients will be treated with 4 cycles, followed by surgical resection if possible. If indicated, surgery may take place prior to the completion of 4 cycles.
Corticosteroid
Combination Therapy for Acute Lymphoblastic Leukemia
Recruiting3 awardsPhase 2
Boston, Massachusetts
This trial will study a new multi-drug chemotherapy regimen for treating Acute Lymphoblastic Leukemia in adults. The regimen includes drugs that have been used to treat pediatric patients in the past, as well as new drugs PEG-asparaginase and E. coli asparaginase. Researchers hope to learn more about the disease and how it responds to standard chemotherapy drugs.
View More Gleevec Trials
See another 10 medical studies focused on gleevec.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.